Georgia Erbez Biography and Net Worth

Chief Financial Officer and Chief Business Officer of Codexis

Georgia Erbez is a seasoned financial and operations executive who joined Codexis as Chief Financial Officer in September 2024 and added the additional role of Chief Business Officer in November 2025. Prior to joining Codexis, she served as Chief Operating Officer at Walking Fish Therapeutics, a private B cell therapy company. Prior to that, she served as the Chief Financial Officer of Harpoon Therapeutics, a public T cell therapy company. Ms. Erbez held the role of Chief Business Officer and Chief Financial Officer at Zosano Pharma Corp., and has served as Chief Financial Officer for Revolution Medicines, Asterias Biotherapeutics and Raptor Pharmaceuticals. Earlier in her career, Ms. Erbez held senior positions in investment banking at Cowen and Company and Jefferies. In addition, she was a Managing Director at Axiom Financial Partners, a life-sciences consulting firm. She currently serves as a member of the board of directors of Coherus BioSciences. Ms. Erbez holds a bachelor’s degree in international relations with an emphasis on economics from the University of California, Davis.

What is Georgia Erbez's net worth?: The estimated net worth of Georgia Erbez is at least $147.65 thousand as of February 6th, 2026. Ms. Erbez owns 66,810 shares of Codexis stock worth more than $147,650 as of July 20th. This net worth approximation does not reflect any other assets that Ms. Erbez may own. Learn More about Georgia Erbez's net worth.
How do I contact Georgia Erbez?: The corporate mailing address for Ms. Erbez and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Georgia Erbez's contact information.
Has Georgia Erbez been buying or selling shares of Codexis?: Georgia Erbez has not been actively trading shares of Codexis over the course of the past ninety days. Most recently, Georgia Erbez sold 3,826 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $1.31, for a transaction totalling $5,012.06. Following the completion of the sale, the insider now directly owns 66,810 shares of the company's stock, valued at $87,521.10. Learn More on Georgia Erbez's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Raymond De Vré (Director), Byron Dorgan (Director), Georgia Erbez (Chief Financial Officer and Chief Business Officer), Bernard Kelley (Director), Stefan Lutz (Chief Scientific Officer), Alison Moore (President and CEO), John Nicols (CEO), Kevin Norrett (COO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 35,774 shares worth more than $65,308.44. The most recent insider tranaction occured on June, 11th when Director Vre Raymond De sold 2,605 shares worth more than $6,173.85. Insiders at Codexis own 3.5% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 6/11/2026.

Georgia Erbez Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/6/2026	Sell	3,826	$1.31	$5,012.06	66,810
10/13/2025	Sell	6,239	$2.50	$15,597.50	70,636

Georgia Erbez Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.21

$2.14

$2.27

50 Day Range

MA: $2.48

$2.13

$2.80

2 Week Range

Now: $2.21

$0.96

$3.87

Volume

506,418 shs

Average Volume

812,612 shs

Market Capitalization

$200.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5